Curasense

CuraSen Therapeutics is a clinical-stage biotechnology company focused on developing novel small molecule therapies for neurodegenerative diseases, including Parkinson's disease and Alzheimer's disease. The company's unique approach targets the locus coeruleus-norepinephrine (LC-NE) system to restore adrenergic signaling, which is often compromised early in neurodegeneration. Their lead programs, CST-103 and CST-2032, are selective beta-2 adrenoceptor agonists designed to improve cognitive and motor functions. These agonists are typically co-administered with CST-107, a peripheral beta-blocker, to minimize systemic side effects. CuraSen is backed by a strong syndicate of investors, including 5AM Ventures, AbbVie Ventures, and Johnson & Johnson Innovation.